Autor(es)Metz Stefan W, Martina Byron E, van den Doel Petra, Geertsema Corinne, Osterhaus Albert D, Vlak Just M, Pijlman Gorben P

ResumoChikungunya virus (CHIKV) causes acute illness characterized by fever - long-lasting arthritic symptoms. The need for a safe - effective vaccine against CHIKV infections is on the rise due to on-going vector spread - increasing severity of clinical complications. Here we report the results of a comparative vaccination-challenge experiment in mice using three different vaccine c-idates produced in insect cells by recombinant baculoviruses: (i) secreted (s)E1 - (ii) sE2 CHIKV glycoprotein subunits (2 ?g/immunization), - (iii) CHIKV virus-like particles (VLPs) (1 ?g E2 equivalent/immunization). These experiments show that vaccination with two subsequent administrations of 1 ?g of Matrix M adjuvanted CHIKV VLPs completely protected AG129 mice from lethal CHIKV challenge. Vaccination with E1 - E2 subunits provided partial protection, with half of the mice surviving but with significantly lower neutralizing antibody titres as compared to the VLP vaccinated mice. This study provides evidence that even a modest neutralizing antibody response is sufficient to protect mice from CHIKV infections. Neutralization was the prominent correlate of protection. In addition, CHIKV VLPs provide a superior immune response - protection against CHIKV-induced disease in mice as compared to individual CHIKV-sE1 - -sE2 subunits.

Palavras-ChaveAG129; Chikungunya virus; E1; E2; Subunits; Vaccine; Virus-like particle

ImprentaVaccine, v. 31, n. 51, p. 6092-6096, 2013

DescritoresChikungunya virus - Cell ; Chikungunya virus - Immune response ; Chikungunya virus - Pathogenesis ; Chikungunya virus - Proteins ; Chikungunya virus - Antibodies ; Chikungunya virus - Immune response ; Chikungunya virus - Viral infections ; Chikungunya Virus - Virus ; Chikungunya virus - Vaccine ; Chikungunya virus - Chikungunya fever ; Chikungunya virus - Immunology ; Chikungunya virus - Public health

Data de Publicação:2013